Treatment of HIV infection. Tolerability of commonly used antiretroviral agents

Drug Safety

Volumn 15, Issue 3, 1996, Pages 176-187

  Notermans, Daan W ^a   Van Leeuuwen, Remko ^a   Lange, Joep M A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; ANTIVIRAL ACTIVITY; ANXIETY; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; META ANALYSIS; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RETINA INJURY; REVIEW; VOMITING;

EID: 0029793703     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615030-00003     Document Type: Review

References (118)

1. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1: 575-80
2. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317 (4): 185-91
3. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990; 322 (19): 1333-40
4. Yarchoan R, Perno CF, Thomas RV, et al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988; 1: 76-81
5. Browne MJ, Mayer KH, Chafee SB, et al. 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993; 167 (1): 21-9
6. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic Human immunodeficiency virus infection; a phase I/II study. J Infect Dis 1995; 171: 1166-71
7. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-5
8. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994; 91 (9): 4096-100
9. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995; 92 (7): 2484-8
10. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171 (3): 537-45
11. Pauwels R, Andries K, Debyser Z, et al. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1993; 90 (5): 1711-5
12. Pagano PJ, Chong KT. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha, J Infect Dis 1995; 171 (1): 61-7
13. Fletcher CV, Collier AC, Rhame FS, et al. Foscarnet for suppression of human immunodeficiency virus replication. Antimicrob Agents Chemother 1994; 38 (3): 604-7
14. Ho DD, Hartshorn KL, Rota TR, et al. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 1985; 1: 602-4
15. Kovacs JA, Deyton L, Davey R, et al. Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 111 (4): 280-7
16. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-81
17. Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. AIDS 1994; 8 (3): 313-21
18. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989; 262 (17): 2405-10
19. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-4
20. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68 (3): 1660-6
21. de Jong MD, Loewenthal M, Boucher CA, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994; 169 (6): 1346-50
22. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-71
23. Richman DD. Resistance, drug failure, and disease progression. AIDS Res Hum Retroviruses 1994; 10 (8): 901-5
24. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171 (6): 1411-9
25. Lange JMA. Combination antiretroviral therapy: back to the future? Drugs 1995; 49 Suppl. 1: 32-7
26. Hammer SM, Kessler HA, Saag MS. Issues in combination anti-retroviral therapy: a review. J Acquir Immune Defic Syndr 1994; 7 Suppl. 2: S24-35
27. Johnson VA. Combination therapy: more effective control of HIV type 1? AIDS Res Hum Retroviruses 1994; 10 (8): 907-12
28. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333 (7): 450-1
29. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. Ann Intern Med 1990; 112 (10): 727-37
30. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329 (5): 297-303
31. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322 (14): 941-9
32. Yarchoan R, Pluda JM, Thomas RV, et al. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990; 336: 526-9
33. Nguyen BY, Yarehoan R, Wyviil KM, et al. Five-year follow-up of a phase 1 study of didanosine in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171 (5): 1180-9
34. Moyle GJ, Nelson MR, Hawkins D, et al. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT). Am J Med 1993; 86 (3): 155-63
35. Jablonowski H, Arasteh K, Staszewski S, et al. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. AIDS 1995; 9: 463-9
36. Merigan TC, Skowron G, Bozzette SA, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I and II study. Ann Intern Med 1989; 110 (3): 189-94
37. Merigan TC, Skowron G. Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Am J Med 1990; 88 Suppl. 5B: 11S-5S
38. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122 (1): 24-32
39. Fischl MA, Oison RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993; 118 (10): 762-9
40. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994; 330 (10): 657-62
41. Fogelman I, Lim L. Bassett R, et al. Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. J Acquir Immune Defic Syndr 1994; 7 (10): 1057-63
42. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990; 113 (2): 111-7
43. Sahai J, Gallicano K, Pakuts A, et al. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994; 169 (5): 1103-7
44. Mole L, Israelski D, Bubp J, et al. Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. J Acquir Immune Defic Syndr 1993; 6 (1): 56-60
45. Kavesh NG, Holzman RS, Seidlin M. The combined toxicity of azidothymidine and antimycobacterial agents. A retrospective study. Am Rev Respir Dis 1989; 139 (5): 1094-7
46. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidolhymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317 (4): 192-7
47. Dournon E, Matheron S, Rozenbaum W, et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988; II: 1297-302
48. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA 1988; 260 (20): 3009-15
49. van Leeuwen R, van den Hurk PJ, Jobsis GJ, et al. Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection. Genitourin Med 1990; 66 (6): 418-22
50. Kimura S, Matsuda J, Ikematsu S, et al. Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS. AIDS 1990; 4 (12): 1251-5
51. van der Wouw PA, van Leeuwen R, van Oers RH, et al. Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study. Br J Haematol 1991: 78 (3): 319-24
52. Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991; 9(5): 802-8
53. Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991; 77 (10): 2109-17
54. Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989; 169 (3): 933-51
55. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323 (15): 1009-14
56. Collier AC, Bozzette S, Coombs RW, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323 (15): 1015-21
57. Nordic Medical Research Councils' HIV Therapy Group. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 1992; 304: 13-7
58. Sande MA, Carpenter CC, Cobbs CG, et al. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. JAMA 1993; 270 (21): 2583-9
59. Le Bras P, D'Oiron R, Quertainmont Y, et al. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? AIDS 1994; 8 (5): 716-7
60. Swartz MN. Mitochondrial toxicity - new adverse drug effects. N Engl J Med 1995; 333: 1146-8
61. Chen C-H, Vazquez-Padua M, Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39: 625-8
62. Gertner E, Thurn JR, Williams DN, et al. Zidovudine-associated myopathy. Am J Med 1989; 86 (6 Pt 2): 814-8
63. Peters BS, Winer J, Landon DN, et al. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Am J Med 1993; 86 (1): 5-15
64. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322 (16): 1098-105
65. Chattha G, Arieff AI, Cummings C, et al. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118 (1): 37-9
66. Dubin G, Braffman MN. Zidovudine-induced hepatotoxicity. Ann Intern Med 1989; 110(1): 85-6
67. Lai KK, Gang DL, Zawacki JK, et al. Fulminant Hepatic Failure Associated with 2′,3′-Dideoxyinosine (ddI). Ann Intern Med 1991; 115: 283-4
68. Freiman JP, Helfert KE, Hamrell MR. et al. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993; 7 (3): 379-85
69. Schneiderman DJ, Arenson DM, Cello JP, et al. Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS). Hepatology 1987; 7: 925-30
70. Connolly KJ, Allan JD, Fitch H, et al. Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am J Med 1991; 91 (5): 471-8
71. Schindzielorz A, Pike I, Daniels M, et al. Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clin Infect Dis 1994; 19 (6): 1076-83
72. Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. Ann Intern Med 1994; 120 (5): 360-8
73. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327 (9): 581-7
74. Montaner JS, Rachlis A, Beaulieu R, et al. Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program. J Acquir Immune Defic Syndr 1994; 7 (9): 924-30
75. 3. Ann Intern Med 1995; 123: 561-71
76. Whitcup SM, Butler KM, Caruso R, et al. Retinal toxicity in human immunodeficiency virus-infected children treated with 2′,3′-dideoxyinosine. Am J Ophthalmol 1992; 113 (1): 1-7
77. Whitcup SM, Dastgheib K, Nussenblatt RB, et al. A clinicopathologic report of the retinal lesions associated with didanosine. Arch Ophthalmol 1994; 112 (12): 1594-8
78. Nguyen BY, Shay LE, Wyvill KM, et al. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycylidine in patients with severe human immunodeficiency virus infection. J Infect Dis 1993; 168 (4): 810-7
79. Cotes JA, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992; 36 (1): 202-5
80. Chang CN, Doong SL, Zhou JH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 267 (20): 13938-42
81. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerascs alpha, beta, and gamma. Antimicrob Agents Chemother 1992; 36 (8): 1688-94
82. van Leeuwen R, Lange JM, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992; 6 (12): 1471-5
83. Pluda JM, Cooley TP, Montaner JS, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171 (6): 1438-47
84. Skowron G. Biologic effects and safety of slavudine: overview of phase I and II clinical trials. J Infect Dis 1995; 171 Suppl. 2: S113-7
85. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis 1995; 171 Suppl. 2: S123-30
86. Skowron G, Squires K, Bowers J, et al. Safety of stavudine (d4T) in AZT-intolerant subjects [abstract PoB 3029]. VIII International Conference on AIDS/III STD World Congress: 1992 Jul 19-24; Amsterdam: B91
87. 3 after at least 6 months' ZDV treatment [abstract I170]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco, 235
88. Yarchoan R, Lietzau JA, Nguyen BY, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994; 169 (1): 9-17
89. Skowron G, Bozette SA, Lim L, et al. Alternating and intermittent regimens of zidovudine and dideoxyeytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993; 118 (5): 321-30
90. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 1992; 116 (1): 13-20
91. Pizzo PA, Butler K, Balis F, et al. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Pediatr 1990; 117 (5): 799-808
92. Gerstoft J, the Nordic HIV Therapy Group. Alternating treat ment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection The ALTER study [abstract 82]. The Fifth European Conference on Clinical Aspects and Treatment of HIV Infection: 1995 Sep 26-29; Copenhagen, 10
93. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993; 119 (8): 786-93
94. Ragni MV, Amato DA, LoFaro ML, et al. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhetnophilic subjects with asymptomatic human immunodeficiency virus-1 infection. Blood 1995; 85 (9): 2337-46
95. Schooley RT, Ramirez-Ronda C, Lange JMA, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared to zidovudine monotherapy. J Infect Dis 1996; 173: 1354-66
96. 3. Fifth European Conference on Clinical Aspects and Treatment of HIV Infection: 1995 Sep 26-29: Copenhagen
97. Yeni P, the International Coordinating Committee. Preliminary results of the European/Australian delta trial: based on data up to 31st May, 1995. Fifth European Conference on Clinical Aspects and Treatment of HIV Infection: 1995 Sep 26-29; Copenhagen
98. Eron JJ, Benoitt SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 cd4+ cells per cubic millimeter. N Engl J Med 1995; 333: 1662-9
99. Bartlett J, Benoit S, Sepulveda G, et al. A randomised double-blind multicenter comparative trial of Lamuvidine (3TC)/ Zidovudine (ZDV) combination therapy vs ZDV/ Dideoxycytidine (ddC) combination therapy in ZDV experienced patients Cd4 100-300mm3 [abstract Lb35]. Second National Conference on Human Retroviruses and Related Infections: 1995 Jan 29-Feb 2; Washington, DC, 173
100. 3 [abstract 7.6]. Second International Congress on Drug Therapy in HIV Infection: 1994 Nov 18-22, Glasgow, S7
101. Katlama C, the European Lamivudine HIV Working Group. Combination 3TC (Lamivudine)/ZDV (Zidovudine) vs ZDV monotherapy in naive HIV-I positive patients with CD4 of 100-400 Cells/mm3 [abstract 7.5]. Second International Congress on Drug Therapy in HIV Infection: 1994 Nov 18-22 Glasgow, S6
102. Mitsuya H, Broder S. Strategies for antiviral therapy in AIDS. Nature 1987; 325: 773-8
103. Smith MS, Pagano JS. Inhibition of human immunodeficiency virus type 1 replication by guanosine analogues and lack of synergistic antiviral effect of acyclovir with 3′-azido-3′-deoxythymidine. Antiviral Chem Chemother 1991; 2: 29-34
104. Surbone A, Yarchoan R, McAtee N, et al. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3′-azido-2′,3′-dideoxythymidine (azidothymidine or zidovudine) and acyclovir: a pilot study. Ann Intern Med 1988; 108 (4): 534-40
105. Cooper DA, Pehrson PO, Pedersen C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. AIDS 1993; 7 (2): 197-207
106. Stein DS, Graham NM, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med 1994; 121 (2): 100-8
107. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8 (2): 141-51
108. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV infection: a randomised double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 1019-30
109. de Wit R. Schattenkerk JKME, Boucher CA, et al. Clinical and virological effects of high-dose recombinant interferon-α in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988; 11: 1214-7
110. Krown SE, Gold JW, Niedzwiecki D, et al. Interferon-alpha with zidovudine: safely, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112 (11): 812-21
111. de Wit R, Danner SA, Bakker PJ, et al. Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma. J Intern Med 1991; 229 (1): 35-40
112. Lane HC, Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection: a randomized, placebo-controlled trial. Ann Intern Med 1990; 112 (11): 805-11
113. Frissen PH, van der Ende ME, ten Napel CH, et al. Zidovudine and inlerferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type I infection. J Infect Dis 1994; 169 (6): 1351-5
114. 6/l results of the Zidon trial. AIDS 1995; 9: 1025-35
115. Vella S. HIV therapy advances: update on a proteinase inhibitor. AIDS 1994; 8 Suppl. 3: S25-9
116. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with suquinavir, zidovudine and zalcitabine. N Engl J Med 1996; 334: 1011-7
117. Pollard R, Peterson D, Hardy D, et al. Antiviral effect and safety of stavudine (d4t) and didanosine (ddI) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blinded trial [abstract nr. 197]. 3rd Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington, DC, 89
118. Mazzulli T, Rusconi S, Merrill DP, et al. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother 1994; 38 (4): 656-61